Rodriguez-Iglesias, Miguel , Calvo-Henriquez, Christian , Martin-Jimenez, Daniel , Garcia-Lliberos, Ainhoa , Maza-Solano, Juan , MORENO LUNA, RAMÓN, Izquierdo-Dominguez, Adriana , Martinez-Capoccioni, Gabriel , Alobid, Isam
No
Curr. Allergy Asthma Rep.
Review
Científica
05/02/2025
001413922700001
Purpose of ReviewChronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.Recent FindingsSignificant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms.SummaryThe findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.
Biologic therapy; Chronic rhinosinusitis with nasal polyps; Dupilumab; Monoclonal antibody; Quality of life